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Summary Valproic acid (VPA) is considered to be a drug of first choice for the
therapy of generalized and focal epilepsies. Due to its broad field of application and its
good compatibility, VPA is one of the most frequently prescribed antiepileptic drugs
(AED) worldwide.
Previous studies have examined the safety and tolerability of rapid intravenous-
loaded VPA in the treatment of epilepsy and status epilepticus, but rapid oral loading
has not been evaluated in paediatrics systematically in the past.
The standard titration scheme takes 10—14 days, some physicians prefer a slower
titration of up to 4 weeks. At many institutes, especially children are treated as
inpatients until the desired dosage is reached. This causes high costs to the health
system and is very inconvenient for the families affected.
We have developed a new loading scheme to achieve a therapeutic serum level on
the third day of treatment, in order to minimize the time between the beginning of
the therapy and reaching the therapeutic serum level. This is the first attempt at
doing this with VPA for children with epilepsy.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Original letter
For at least 30 years Valproic acid has been used as a
highly efficacious antiepileptic medication for the
therapy of generalized and focal epilepsy in children
and adults and bipolar disorder1 and migraine pro-
phylaxis.2
The standard-titration is careful and slow, to
avoid incompatibilities, including cognitive side
effects and rashes.3 Commonly the dosage ranges
from 5 to 7.5 mg/(kg day) with an increase of
5—7.5 mg/(kg day) every 3—7 days up to a final* Corresponding author. Tel.: +49 6213832466.
E-mail address: thorsten-gerstner@web.de (T. Gerstner).
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doi:10.1016/j.seizure.2006.09.005dosage of 30 mg/(kg day) in children and 20—
25 mg/(kg day) in adolescents and adults. A suffi-
cient serum level is reached after 2—6 weeks.
Intravenous rapid loading is possible and well
tolerated,4 whereas the VPA pharmacokinetics are
dependent on age, induction status, and formula-
tion.5 An oral scheme has already been established
for phenytoin.6
A rapid oral loading of VPA was suggested for the
therapy of acute mania for adult psychiatric
patients.7,8 Good et al.9 showed the possibility of
quick oral loading of VPA in child psychiatry inpa-
tients with a dosage of 15 mg/(kg BW) after a period
of 5 days. Side effects were observed in overweight
children.9. Published by Elsevier Ltd. All rights reserved.
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As opposed to the saturation scheme of Martinez
et al.8 used in acute manic adults, we have initiated
a scheme for rapid oral saturation, starting with
30 mg/kg as single dose, followed by 45 mg/kg on
the second day divided in two doses and 30 mg/
(kg day) on day 3 for children with epilepsy. The
serum level of VPA, coagulation parameters, trans-
aminases, lipase and full blood count were con-
trolled on the third day of therapy.Results
We have applied this scheme in 35 children (as
shown in Table 1) and adolescents in our hospital.
Twenty-one were male, 14 female, the age rangedTable 1 Children, achieved the new oral rapid saturation
Patient Sex Age
(years)
Epilepsy syndrome
1 m 1 Partial lissencephaly
2 f 13 IGE
3 m 15 IGE
4 m 2 Herpes encephalitis
5 m 1 SDB
6 f 5 Relapsing febrile convulsions
7 m 16 Benign focale
8 m 4 West syndrome
9 m 3 Infantile grand-mal epilepsy
10 m 8 Absence-epilepsy
11 m 4 Partial onset with secondary g
12 f 3 Infantile grand-mal epilepsy
13 f 16 IGE
14 f 2 WEST syndrome
15 f 2 Infantile grand-mal epilepsy
16 m 1 Lissencephaly
17 m 9 IGE
18 f 7 Partial onset with secondary g
19 f 3 Infantile grand-mal epilepsy
20 f 2 Infantile grand-mal epilepsy
21 f 1 Infantile grand-mal epilepsy
22 m 13 Epilepsy with grand-mal on aw
23 m 0.9 Absence-epilepsy
24 m 2 Relapsing febrile convulsions
25 f 9 IGE
26 f 1 Relapsing febrile convulsions
27 m 8 IGE
28 m 1 Encephalopathy
29 m 1 Infantile grand-mal epilepsy
30 m 3 Infantile grand-mal epilepsy
31 f 16 Epilepsy with grand-mal on aw
32 m 2 Infantile grand-mal epilepsy
33 m 9 IGE
34 m 6 IGE
35 f 0.7 Relapsing febrile convulsions
IGE: idiopathic generalized epilepsy; SDB: subdural bleeding; SUL:from 9 months up to 16 years (average 5.5 years).
The spectrum of diseases ranged from relapsing
febrile convulsions, grand-mal epilepsy to epilepsy
with grand-mal on awakening (Janz-Syndrome).
All of the patients reached a sufficient fasting
serum level of VPA on the third day (average
98.2 mg/l; median 101 mg/l; 48—146 mg/l). Two
of the patients, 14 and 16 years old, both with
juvenile myoclonic epilepsy had maximum serum
levels of 140 and 146 mg/l, respectively, and devel-
oped an increase of the serum ammonia level (98
and 200 mmol/l) with nausea and fatigue. Shortly
after we reduced the daily dosage, the symptoms
disappeared and the serum ammonia level normal-
ized. All other children did not complain of any side
effects, such as drowsiness and other CNS side
effects or gastrointestinal adverse reactions during
the first 30 days of treatment. No alterations of anyscheme
Add.
AED
VPA-level
day 3 (mg/l)
VPA-level
day 30 (mg/l)
TPM 84 99
— 79 82
— 76 86
— 56 82
TPM 127 100
— 71 85
— 102 98
SUL 48 138
— 61 91
— 112 103
eneralisation — 96 102
— 101 97
— 91 102
TPM 113 61
— 110 77
TPM 123 80
— 86 77
eneralisation — 115 72
— 50 51
109 109
— 87 92
akening 146 111
115 76
86 102
113 43
122 84
127 127
TPM 88 85
109 109
— 87 87
akening — 140 79
— 126 102
89 92
123 77
— 83 92
sulthiame; TPM: topiramate.
632 T. Gerstner et al.laboratory findings were discerned, seizure control
was achieved and remained excellent thereafter.
We controlled the fasting serum level of VPA 30
days later and the serum level was still at a ther-
apeutic level (average 97.8 mg/l; median 91 mg/l).Conclusion
Our findings suggest that a new rapid titration
scheme of oral VPA-treatment is feasible. We
reached a sufficient serum level on the third day
of therapy and the patients did not show any severe
side effects or incompatibilities.
Two of our patients, both adolescents, showed a
mild increase of the serum ammonia level related to
a high serum level of VPA. In these two adolescents
we applied the same dosage of 30 mg/(kg BW) as in
the children. Commonly a final dosage of 20 mg/
(kg BW) is aimed at in adolescents and adults as
compared to 30 mg/(kg BW) in infants. The side
effects we encountered in the adolescents corrobo-
rate the clinical experience that 20 mg/(kg BW)
should be aimed at this age group.
The results suggest that VPA can be safely adminis-
tered by rapid oral loading in children with epilepsy
andthatusingastandardloadingprotocolcanresult in
therapeutic serum levels in patients in 3 days or less.
In contrast to the conventional scheme, our
newly initiated rapid oral loading of VPA shortens
the time as inpatient and in consequence the costs
and the inconvenience caused to the families.
Furthermore, seizure control can be obtained much
faster than with conventional loading schemes.In contrast to intravenous rapid loading our new
scheme is less invasive and less painful, but also very
effective.
Our next step is to prospectively compare our
new scheme versus the standard titration.References
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